Collaborative Platform Trials to Fight COVID-19: Methodological and Regulatory Considerations for a Better Societal Outcome.
Saved in:
| Title: | Collaborative Platform Trials to Fight COVID-19: Methodological and Regulatory Considerations for a Better Societal Outcome. |
|---|---|
| Authors: | Collignon O; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Burman CF; Statistical Innovation, Data Science, and Artificial Intelligence, AstraZeneca R&D, Gothenburg, Sweden., Posch M; Section for Medical Statistics, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria., Schiel A; Norwegian Medicines Agency, Oslo, Norway. |
| Source: | Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Aug; Vol. 110 (2), pp. 311-320. Date of Electronic Publication: 2021 Mar 16. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1532-6535 |
|---|---|
| DOI: | 10.1002/cpt.2183 |
